120 related articles for article (PubMed ID: 37975575)
1. Reaching the cyclosporine a level target slowly in four weeks correlates with better prognosis for Chinese patients after allogeneic haematopoietic cell transplantation.
Fan Q; Hui X; Li X; Li Q; Yang D; Wang Y
Hematology; 2023 Dec; 28(1):2275893. PubMed ID: 37975575
[TBL] [Abstract][Full Text] [Related]
2. Impact of cyclosporine-A concentration in T-cell replete haploidentical allogeneic stem cell transplantation.
Yang X; Yang S; Sun A; Qiu H; Tang X; Han Y; Wu D
Clin Transplant; 2018 Apr; 32(4):e13220. PubMed ID: 29493007
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation.
de Kort EA; de Lil HS; Bremmers MEJ; van Groningen LFJ; Blijlevens NMA; Huls G; Brüggemann RJM; van Dorp S; van der Velden WJFM
PLoS One; 2019; 14(3):e0213913. PubMed ID: 30897127
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943
[TBL] [Abstract][Full Text] [Related]
5. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M
Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
[TBL] [Abstract][Full Text] [Related]
6. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
[TBL] [Abstract][Full Text] [Related]
7. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.
Stocker N; Duléry R; Battipaglia G; Brissot E; Médiavilla C; Sestili S; Paviglianiti A; Ledraa T; Mohty R; Bazarbachi A; Belhocine R; Vekhoff A; Ruggeri A; Mohty M; Malard F
Eur J Haematol; 2019 Jul; 103(1):10-17. PubMed ID: 30958904
[TBL] [Abstract][Full Text] [Related]
8. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
9. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiota intervention by pre and probiotics can induce regulatory T cells and reduce the risk of severe acute GVHD following allogeneic hematopoietic stem cell transplantation.
Yazdandoust E; Hajifathali A; Roshandel E; Zarif MN; Pourfathollah AA; Parkhideh S; Mehdizadeh M; Amini-Kafiabad S
Transpl Immunol; 2023 Jun; 78():101836. PubMed ID: 37037266
[TBL] [Abstract][Full Text] [Related]
11. Premature cyclosporine cessation and TBI-containing conditioning regimen increase the risk of acute GvHD in children undergoing unrelated donor hematopoietic stem cell transplantation.
Szmit Z; Kałwak K; Król A; Mielcarek-Siedziuk M; Salamonowicz M; Frączkiewicz J; Ussowicz M; Owoc-Lempach J; Gorczyńska E
Adv Clin Exp Med; 2019 Sep; 28(9):1185-1192. PubMed ID: 31430073
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M
Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681
[TBL] [Abstract][Full Text] [Related]
13. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
Front Immunol; 2020; 11():1534. PubMed ID: 32849519
[No Abstract] [Full Text] [Related]
15. Low cyclosporine concentrations in children and time to acute graft versus host disease.
Chung EK; Yee J; Kim JY; Gwak HS
BMC Pediatr; 2020 May; 20(1):206. PubMed ID: 32393210
[TBL] [Abstract][Full Text] [Related]
16. Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.
Yu J; Parasuraman S; Shah A; Weisdorf D
Curr Med Res Opin; 2019 Jun; 35(6):983-988. PubMed ID: 30461314
[TBL] [Abstract][Full Text] [Related]
17. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
18. Feasibility of Cyclosporine Prophylaxis Withdrawal in Critically Ill Allogenic Hematopoietic Stem Cell Transplant Patients Admitted to the Intensive Care Unit With No GVHD.
Saillard C; Legal PH; Furst S; Bisbal M; Servan L; Sannini A; Gonzalez F; Faucher M; Vey N; Blaise D; Chow-Chine L; Mokart D
Transplant Cell Ther; 2022 Nov; 28(11):783.e1-783.e10. PubMed ID: 35964937
[TBL] [Abstract][Full Text] [Related]
19. The stability of initial tacrolimus concentration following allogeneic hematopoietic stem cell transplantation reduces the risk of acute GVHD.
Okabe M; Morishita T; Ichiki T; Kawaguchi Y; Lee Y; Ohbiki M; Goto M; Osaki M; Araie H; Goto T; Ozawa Y; Miyamura K
Clin Transplant; 2020 Oct; 34(10):e14052. PubMed ID: 33427361
[TBL] [Abstract][Full Text] [Related]
20. Post-transplantation Cyclophosphamide-based Graft-versus-host-disease Prophylaxis Compared to Methotrexate-cyclosporine a in Matched-related Allogeneic Hematopoietic Stem Cell Transplantation.
Shouman MT; Mansour OM; El Gammal MM; Abdel-Fattah RM; Samra MA; Elhaddad AM; Maher MA; Mahmoud HK
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):379-387. PubMed ID: 37363983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
